

### **INTERVIEW SUMMARY**

An in person interview was held between Applicants' representative, Mr. Scott Smith, and the Examiner on February 7, 2008. During the interview each of the objections and rejections of record were discussed. Applicants and Examiner agreed that by amending pending independent claims 35, 59, and 60 to eliminate the use of hydroxypropyl methylcellulose derivative and glycerol monostearate as well as the phrase "at least 95 wt% of the cilostazol is suspended in the composition" would overcome the pending rejections under 35 U.S.C. 112, first paragraph. Further it was agreed that by amending the phrase "wherein the cilostazol is released over an extended period of time" found in each of claims 35, 59, and 60 to read "wherein the composition is formulated to release the cilostazol over an extended period of time, said extended period of time being between 2 and 24 hours" the pending rejection under 35 U.S.C. § 101 would be overcome. The impact of such amendments on the relevancy of the presently cited reference as well as the novelty and the inventive nature of the present invention were also discussed